Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.60 |
| ▸ | CCNC | P24863 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216015 | 0.90 | CDK8 (0.69) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12256427 | 0.89 | CDK8 (0.67) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL378881 | 0.88 | CDK8 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2443743 | 0.86 | CDK8 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1284027 | 0.84 | JAK2 (0.81) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600309 | 0.83 | CDK8 (0.82) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1599571 | 0.83 | CDK8 (0.69) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6837515 | 0.81 | CDK8 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL9967321 | 0.81 | CDK8 (0.78) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3190583 | 0.81 | MAPK14 (0.58) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |